4pa4: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='4pa4' size='340' side='right' caption='[[4pa4]], [[Resolution|resolution]] 3.02Å' scene=''> | <StructureSection load='4pa4' size='340' side='right' caption='[[4pa4]], [[Resolution|resolution]] 3.02Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4pa4]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PA4 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PA4 FirstGlance]. <br> | <table><tr><td colspan='2'>[[4pa4]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Magmm Magmm]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PA4 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PA4 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=12P:DODECAETHYLENE+GLYCOL'>12P</scene>, <scene name='pdbligand=2CV:HEGA-10'>2CV</scene>, <scene name='pdbligand=BR:BROMIDE+ION'>BR</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=12P:DODECAETHYLENE+GLYCOL'>12P</scene>, <scene name='pdbligand=2CV:HEGA-10'>2CV</scene>, <scene name='pdbligand=BR:BROMIDE+ION'>BR</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4cbc|4cbc]], [[4p90|4p90]], [[4p2z|4p2z]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4cbc|4cbc]], [[4p90|4p90]], [[4p2z|4p2z]]</td></tr> | ||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Mmc1_0798 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=156889 MAGMM])</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4pa4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4pa4 OCA], [http://pdbe.org/4pa4 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4pa4 RCSB], [http://www.ebi.ac.uk/pdbsum/4pa4 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4pa4 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4pa4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4pa4 OCA], [http://pdbe.org/4pa4 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4pa4 RCSB], [http://www.ebi.ac.uk/pdbsum/4pa4 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4pa4 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| Line 21: | Line 22: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Magmm]] | |||
[[Category: Bagneris, C]] | [[Category: Bagneris, C]] | ||
[[Category: Naylor, C E]] | [[Category: Naylor, C E]] | ||
Revision as of 17:47, 15 November 2017
Structural highlights
Publication Abstract from PubMedVoltage-gated sodium channels are important targets for the development of pharmaceutical drugs, because mutations in different human sodium channel isoforms have causal relationships with a range of neurological and cardiovascular diseases. In this study, functional electrophysiological studies show that the prokaryotic sodium channel from Magnetococcus marinus (NavMs) binds and is inhibited by eukaryotic sodium channel blockers in a manner similar to the human Nav1.1 channel, despite millions of years of divergent evolution between the two types of channels. Crystal complexes of the NavMs pore with several brominated blocker compounds depict a common antagonist binding site in the cavity, adjacent to lipid-facing fenestrations proposed to be the portals for drug entry. In silico docking studies indicate the full extent of the blocker binding site, and electrophysiology studies of NavMs channels with mutations at adjacent residues validate the location. These results suggest that the NavMs channel can be a valuable tool for screening and rational design of human drugs. Prokaryotic NavMs channel as a structural and functional model for eukaryotic sodium channel antagonism.,Bagneris C, DeCaen PG, Naylor CE, Pryde DC, Nobeli I, Clapham DE, Wallace BA Proc Natl Acad Sci U S A. 2014 May 21. pii: 201406855. PMID:24850863[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||||